Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (796)	4/20/2001 11:27:14 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 834

From FT. Taking DNA down 4+ on this news was unnecessary, though with the asthma drug being FDA'd and that business about the bleeding lungs, someone might just be worried about the pipe. >>Veletri was discovered by Roche, the Swiss pharmaceuticals giant, but spun out to Actelion three years ago as part of a re-focusing of priorities. The Roche pedigree had been seen as an endorsement of the drug's chances of success. However, one analyst said taking on unwanted products from pharmaceutical companies was a risky strategy. "Big pharma don't give away freebies," he said. The failure of Veletri leaves Actelion dependent on Tracleer, a treatment under development for pulmonary hypertension and chronic heart failure. << Wilder